Foghorn sounds another warning about the class of ‘20
In 2020 76 biotech floats raised a combined $12.7bn. Foghorn is not the first to show that much of the faith was misplaced.
Venture financing holds steady for device makers
Medtech VCs have plenty of cash, which is just as well because the IPO window is shut and locked.
For medtechs seeking deals, it’s hurry up and wait
Last year venture-backed companies waited longer than average for a takeout, and longer than ever for an IPO.
Flotations tank in the first quarter
A correction – as long as it is not too severe – might not be a bad thing for the sector.
Crunch time for the Spac space
This month has seen two blank-cheque company deals fall apart, and more terminations should be expected.
